Pfizer, Biogen swap control of schizophrenia treatment
March 13, 2018
Pharmaceuticals | New York, NY | Corporate Acquisition
Biogen has agreed to acquire a treatment for cognitive impairment associated with schizophrenia from pharmaceutical giant Pfizer. The purchase includes an upfront payment of $75 million and up to $515 million in additional development and commercialization milestone payments along with tiered royalties. Biogen plans to start Phase II-B trials for the treatment in the second half of 2018.